CD163 and neoplasm: Similarly, PIR-B or PD-L1 inhibition reduced the proportion of CD206+ and CD163+ TAMs but elevated that of CD86+ and CD80+ TAMs in tumor tissues with the most obvious alteration in the combined blockade group (Figure 6G-H, Figure S6D-G).